Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus OTIPRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus OTIPRIO.
DEFLAZACORT vs OTIPRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
1 mg/kg intravenous infusion over 1 hour every 12 hours; typical adult dose is 100 mg every 12 hours.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Mean terminal elimination half-life is approximately 4.5 hours (range 3-6 hours); prolonged in renal impairment requiring dose adjustment.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Primarily renal excretion of unchanged drug (approximately 80% over 24 hours) via glomerular filtration; biliary/fecal elimination accounts for <5%.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."